317 related articles for article (PubMed ID: 15029079)
1. [Mémantine (Ebixa): a new therapeutic strategy for the treatment of moderate to severe forms of Alzheimer's disease].
Gallarda T; Lôo H
Encephale; 2004; 30(1):69-79. PubMed ID: 15029079
[TBL] [Abstract][Full Text] [Related]
2. Memantine: a review of its use in Alzheimer's disease.
Robinson DM; Keating GM
Drugs; 2006; 66(11):1515-34. PubMed ID: 16906789
[TBL] [Abstract][Full Text] [Related]
3. Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer's disease?
Doggrell S
Expert Opin Pharmacother; 2003 Oct; 4(10):1857-60. PubMed ID: 14521495
[TBL] [Abstract][Full Text] [Related]
4. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
Lipton SA
J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
[TBL] [Abstract][Full Text] [Related]
5. Memantine for dementia.
Areosa Sastre A; McShane R; Sherriff F
Cochrane Database Syst Rev; 2004 Oct; (4):CD003154. PubMed ID: 15495043
[TBL] [Abstract][Full Text] [Related]
6. Memantine in moderate-to-severe Alzheimer's disease.
Reisberg B; Doody R; Stöffler A; Schmitt F; Ferris S; Möbius HJ;
N Engl J Med; 2003 Apr; 348(14):1333-41. PubMed ID: 12672860
[TBL] [Abstract][Full Text] [Related]
7. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
Wilcock GK; Ballard CG; Cooper JA; Loft H
J Clin Psychiatry; 2008 Mar; 69(3):341-8. PubMed ID: 18294023
[TBL] [Abstract][Full Text] [Related]
8. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
[TBL] [Abstract][Full Text] [Related]
9. Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors.
Grossberg GT; Alva G; Hendrix S; Ellison N; Kane MC; Edwards J
Alzheimer Dis Assoc Disord; 2018; 32(3):173-178. PubMed ID: 29771687
[TBL] [Abstract][Full Text] [Related]
10. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.
Bakchine S; Loft H
J Alzheimers Dis; 2008 Feb; 13(1):97-107. PubMed ID: 18334761
[TBL] [Abstract][Full Text] [Related]
11. Rationalizing therapeutic approaches in Alzheimer's disease.
Grossberg GT
CNS Spectr; 2005 Nov; 10(11 Suppl 18):17-21. PubMed ID: 16273026
[TBL] [Abstract][Full Text] [Related]
12. Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias.
Thomas SJ; Grossberg GT
Clin Interv Aging; 2009; 4():367-77. PubMed ID: 19851512
[TBL] [Abstract][Full Text] [Related]
13. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
[TBL] [Abstract][Full Text] [Related]
14. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.
van Dyck CH; Schmitt FA; Olin JT;
Am J Geriatr Psychiatry; 2006 May; 14(5):428-37. PubMed ID: 16670247
[TBL] [Abstract][Full Text] [Related]
15. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
Lipton SA
Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
[TBL] [Abstract][Full Text] [Related]
16. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
Sonkusare SK; Kaul CL; Ramarao P
Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of memantine in the treatment of Alzheimer's disease].
Molinuevo Guix JL; Lladó Plarrumaní A
Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
[TBL] [Abstract][Full Text] [Related]
18. Memantine for dementia.
Areosa SA; Sherriff F
Cochrane Database Syst Rev; 2003; (1):CD003154. PubMed ID: 12535459
[TBL] [Abstract][Full Text] [Related]
19. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.
Winblad B; Jones RW; Wirth Y; Stöffler A; Möbius HJ
Dement Geriatr Cogn Disord; 2007; 24(1):20-7. PubMed ID: 17496417
[TBL] [Abstract][Full Text] [Related]
20. NMDA-antagonism (memantine): an alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia.
Koch HJ; Szecsey A; Haen E
Curr Pharm Des; 2004; 10(3):253-9. PubMed ID: 14754385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
